ClearGazeTest delivers quantitative neurological biomarkers that subjective exam misses — tracking 12 oculomotor parameters at 500 Hz in 5 minutes, with automated scoring and longitudinal trend analysis ready for integration into your clinical workflow.
Neurological exams rely on subjective observation, patient self-report, and cognitive tools developed before high-speed eye tracking existed. ClearGazeTest closes the quantitative gap across the conditions you see most.
SCAT6, ImPACT, and BESS measure symptoms and balance — not the underlying neurological disruption. Oculomotor deficits persist long after symptoms resolve and before they appear, creating both premature return-to-play risk and missed diagnoses in asymptomatic presentations.
MMSE and MoCA capture mid-to-late stage cognitive decline. Oculomotor biomarkers — saccadic latency, smooth pursuit gain, anti-saccade error rates — are disrupted years earlier, offering a quantitative pre-clinical window that verbal-cognitive tools cannot access.
Urine and blood testing detect past exposure, not current function. Real-time oculomotor assessment detects functional CNS depression from alcohol, cannabis, opioids, benzodiazepines, and stimulants — the clinically relevant question is "is this patient impaired now?"
CNS-active medications — benzodiazepines, opioids, antihistamines, anticonvulsants — suppress oculomotor function before patients subjectively notice impairment. Baseline-referenced serial assessment enables objective medication titration and fitness-for-duty evaluation.
BPPV, labyrinthitis, vestibular neuritis, and chronic vestibular dysfunction produce characteristic oculomotor signatures — fixation instability, smooth pursuit breakdown, and convergence error — that enable differentiated diagnosis and objective treatment monitoring.
Balance and gait testing require patient effort and cooperation. Oculomotor biomarkers provide a passive, objective measure of the cerebellar-vestibular integrity that underlies dynamic postural control — particularly valuable in elderly patients and those post-injury.
ClearGazeTest uses infrared binocular video oculography (VOG) — the same fundamental technology used in academic neuroimaging centers — in a portable, automated clinical tool.
Patient performs a brief fixation sequence to establish individual baseline. The system accounts for inter-individual variation in eye morphology and prior neurological history. Baseline is stored for longitudinal comparison on subsequent visits.
Structured stimulus battery: pro-saccade, anti-saccade, smooth pursuit, pupillary light reflex, convergence, fixation stability, and scotopic contrast tasks. Protocol is standardized; no operator skill required for administration.
500 Hz infrared binocular capture is processed algorithmically, computing all 12 biomarker values with normative percentile ranks and deviation flags. No manual scoring. Results available before patient leaves the chair.
Structured PDF with biomarker values, percentile ranks, normative comparison, trend analysis vs. prior assessments, and a plain-language interpretive summary for documentation. HL7 FHIR export available for EHR integration.
| Technical Specifications | |
|---|---|
| Modality | Infrared binocular video oculography (VOG) |
| Sampling Rate | 500 Hz (both eyes, simultaneous) |
| Assessment Duration | ~5 minutes, fully automated |
| Biomarkers | 12 quantitative oculomotor parameters |
| Pupillometry | Constriction velocity, re-dilation slope, hippus amplitude |
| Output | PDF report, HL7 FHIR / EHR export, longitudinal dashboard |
| Normative DB | Age- and sex-stratified population norms |
| Operator Training | Clinical MA or RN; no specialist required |
| Form Factor | Portable; desktop or wall-mount configurations |
| Connectivity | Wi-Fi / LAN; HIPAA-compliant cloud or on-premise |
Each biomarker reflects activity in distinct neural circuits. Together they create a comprehensive functional signature of current CNS integrity.
ClearGazeTest integrates into workflows across neurology, sports medicine, emergency, occupational medicine, geriatrics, and more — each with specialty-specific protocol presets.
Quantitative serial assessment for TBI, stroke, MS, Parkinson's, MCI, and vestibular disorders. Track treatment response and rehabilitation progress with objective oculomotor endpoints.
Objective pre-season baseline, real-time sideline assessment capability, and safe return-to-play decision support grounded in quantitative neurological data — not symptom self-report alone.
Rapid chair-side assessment for altered mental status, suspected intoxication, or head trauma. Quantitative oculomotor signature distinguishes impairment mechanisms — critical for triage and disposition decisions.
Pre-employment baseline, fitness-for-duty evaluation, post-incident assessment, and return-to-work clearance for safety-sensitive positions in aviation, transportation, and heavy industry.
Annual cognitive monitoring, fall risk assessment, medication safety screening, and early detection of neurodegenerative change. Passive, non-demanding assessment ideal for older patients.
Objective pharmacodynamic monitoring for patients on opioids, benzodiazepines, or in recovery. ClearGazeTest provides quantitative CNS depression measurement beyond patient self-report and pill counts.
Standard neurological and cognitive tools were developed for different clinical questions. See where quantitative oculomotor assessment fills the gap.
| Capability | SCAT6 / BESS | ImPACT / MoCA | Standard Eye Exam | ClearGazeTest |
|---|---|---|---|---|
| Quantitative biomarkers (not symptom-based) | ✗ | Partial | ✗ | ✓ |
| Detects impairment before symptoms appear | ✗ | ✗ | ✗ | ✓ |
| Real-time substance impairment detection | ✗ | ✗ | ✗ | ✓ |
| Longitudinal trend / serial monitoring | ✗ | Limited | ✗ | ✓ |
| Medication effect quantification | ✗ | ✗ | ✗ | ✓ |
| Administration time | 20–30 min | 15–25 min | 20–40 min | 5 min |
| Non-specialist administration | ✓ | ✓ | ✗ | ✓ |
| Effort-independent (passive measure) | ✗ | ✗ | Partial | ✓ |
ClearGazeTest biomarkers are derived from decades of published oculomotor neuroscience across neurology, ophthalmology, vestibular medicine, and pharmacology.
ClearGazeTest is designed for practical clinical environments — not research labs. Minimal staff training, no specialist operator, and structured output that documents itself.
HL7 FHIR structured export, PDF addendum, or direct EHR workflow integration for major platforms.
Patient-level trend analysis across visits. Visual biomarker trajectories that support clinical narrative documentation.
No specialist required. Clinical MA or RN can administer the full protocol after standard training. Physician reviews report.
Structured clinical report with biomarker values, normative comparison, trend analysis, and interpretive summary. Chart-ready.
Cloud or on-premise deployment options. All data encrypted at rest and in transit. SOC 2 Type II audit path.
Configurable patient-facing summary for portal delivery — supports engagement and shared decision-making in follow-up discussions.
Assessment aligns with existing CPT codes for neurobehavioral testing, vestibular function, and neuropsychological evaluation. Discuss coding with your billing team.
Specialty-specific protocol configurations — concussion, geriatric, occupational, addiction — each optimized for clinical question and time available.
"Oculomotor assessment is the EKG of the brain — it gives you objective, real-time electrical signatures of neurological function that cannot be faked, coached, or influenced by the patient's effort or subjective report."
The ClearGazeTest report is designed for physician interpretation without prior oculomotor expertise. Each biomarker includes a normative percentile rank, population-referenced deviation flag, and an interpretive plain-language summary. Pattern-based interpretive guidance is included in the clinical reference guide provided at onboarding. For practices wishing to develop deeper expertise, we offer a half-day CME-eligible virtual clinical training module covering oculomotor neuroanatomy, biomarker interpretation, and specialty application.
ClearGazeTest is a quantitative screening and monitoring tool, not a replacement for comprehensive neuro-ophthalmology evaluation when that is clinically indicated. Its strengths are speed (5 minutes), objectivity (quantitative rather than observer-dependent), repeatability (longitudinal trend analysis), and breadth (12 parameters across multiple neural systems). For complex neuro-ophthalmic presentations, ClearGazeTest provides useful objective data that complements, not replaces, specialist evaluation.
ClearGazeTest assessment requires the ability to focus on visual stimuli and follow basic instructions. Patients with severe visual acuity loss, significant strabismus not corrected by glasses, inability to follow simple directions, or acute agitation may yield incomplete or non-interpretable results. The system flags incomplete data segments. Patients with known amblyopia, monocular vision, or significant refractive error should be noted in the record — the system accommodates monocular assessment when binocular data is not feasible. There are no radiation, contact, or pharmacological components; the assessment is non-invasive.
ClearGazeTest produces quantitative, timestamped, instrumentally-derived data — which is a different evidentiary class than observer-dependent clinical findings. In occupational, fitness-for-duty, and regulatory contexts, objective measurement is generally more defensible than subjective assessment. We provide detailed methodology documentation and can provide expert witness support through our clinical advisory network when required. Specific legal admissibility depends on jurisdiction and proceeding type; consult legal counsel for case-specific guidance.
Implementation follows a structured onboarding pathway: hardware installation (half-day), system configuration and EHR integration setup, staff administration training (2–4 hours), and physician clinical interpretation briefing (1–2 hours). Most practices are fully operational within two weeks of delivery. Ongoing support includes dedicated clinical success management, monthly software updates, normative database updates as population data expands, and access to our clinical advisory team for complex interpretation questions. Contact us for a site-specific implementation timeline.
All 12 biomarkers are referenced against an age- and sex-stratified normative population database. Individual result percentile ranks reflect where the patient's values fall within their demographic cohort. The system also builds individual patient baselines over multiple visits, enabling deviation-from-personal-baseline reporting — which is particularly valuable for serial monitoring in concussion management, medication adjustment, and neurodegenerative disease progression tracking. Normative data is continuously updated as the clinical database expands.
Speak with a ClearGazeTest clinical specialist. We'll walk through the assessment workflow, review sample reports from your specialty, and discuss implementation for your practice.
ClearGazeTest · Medical Card Exam
clinical@medicalcardexam.com
We support IRB-approved research protocols and can provide technical documentation, normative data access, and co-investigation partnerships.
Custom implementation pathways for hospital systems, multi-specialty groups, and integrated health networks. Contact our enterprise clinical team.
CME-eligible oculomotor neuroscience training available for clinical teams. Contact us for group training scheduling and CE credit documentation.